FDA approves Octapharma USA IND application for severe COVID-19 patients

(Yankee Public Relations) The US Food and Drug Administration (FDA) has approved the investigational new drug (IND) application submitted by Octapharma USA for a phase three clinical trial on the efficacy and safety of Octagam 10% [Immune Globulin Intravenous (Human)] therapy in COVID-19 patients with severe disease progression.

https://www.eurekalert.org/pub_releases/2020-05/ypr-fao052020.php

Source: EurekAlert! - Infectious and Emerging Diseases - May 20, 2020 Category: Infectious Diseases Source Type: news